(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Instructions to Perceive and Grasp the Early Side effects of Cellular breakdown in the lungs - 2Most loved Web-based feature: Which Stage Do You Like
- 3US FDA declines to approve Corcept's drug for rare hormonal disorder
- 4'Stranger Things' series finale trailer shows Hawkins gang gearing up for last battle with Vecna
- 5Step by step instructions to Advance the Eco-friendliness of Your Kona SUV
- The most effective method to Refresh the Infotainment Framework in the Volvo XC40
- Extremely Rare Snub-Nosed Monkey Was Just Born for the First Time Outside of Asia
- Malaysian broadcaster rejects altered graphic about electricity rate hike
- Smooth countdown continues for Artemis II moon mission
- Israel violated ceasefire with Hezbollah more than 10,000 times, UNIFIL claims
- Evaluated Smartwatches for Wellness Devotees
- Merz says army could be involved in mine-clearing from Hormuz
- US FDA unveils new pathway to approve personalized therapies
- Support Your Body: A Manual for Smart dieting and Sustenance
